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Introduction
Although efficient vaccines, new nucleoside analogs
are available, chronic hepatitis B (HBV) infection is
still a major health problem worldwide [1]. Children
infected early in life who have indication of viral repli-
cation are at the high risk for development of progres-
sive liver disease and are a major source of infection in
others [2]. Treatment options for children are still lim-
ited. The goal of treatment is to prevent the progres-
sion of chronic hepatitis B to long-term complications,
such as cirrhosis and hepatocellular carcinoma, that
can result in death [3].
Lamivudine was the first oral antiviral therapy
approved for the treatment of CHB [4]. Molecular
mechanism of resistance in HBV genome is well
known but the optimal length for children's treatment
with lamivudine required to achieve a durable virolog-
ical response has not been established [5].
Lamivudine resistance is due to the selection of
HBV mutants that undergo mutation in the HBV DNA
polymerase gene. The C domain of the polymerase
gene has a common tyrosine-methionine-aspartate-
aspartate (YMDD) motif essential for polymerase
activity. This conserved motif is involved in nucleotide
binding in the catalytic site of the polymerase [6].
Material and methods
Sera from 27 children with chronic hepatitis B were investigat-
ed in this study. Serum samples were sequentially collected from
children – before, during, after lamivudine treatment and six
months after lamivudine discontinuation. All patients had active
inflammation in the liver and HBeAg presence in serum. Before
lamivudine treatment, children were treated with interferon
alpha in 3MIU 3 times a week for 20 weeks. Lamivudine thera-
py started after unsuccessfully INF alpha treatment due to
schedule: 3-4 mg/kg body weight 1 daily for 1,5 year (max dose
was 100 mg/24h).
HBV DNA extraction. DNA was isolated from children's sera
with Gen Elute™ Mammalian Genomic DNA Miniprep Kit
(Sigma, USA). Amplification of virus's reverse transcriptase
region was achieved by PCR and nested PCR in Gene Amp PCR
System 2400 from Applied Biosystems. Primers were comple-
mentary to conservative part of genome (sense 5'-AG GGG
AGG AGA TTA GGT TAA-3' antisense 5'-AGG AGT GCG AAT
CCA CAC TC-3'). PCR reaction included: 200 mM dNTPs, 0.4
mM all primers, 1.5 mM MgCL2, 1.0 U Taq polymerase
(Sigma). Thermal profile of PCR: 96°C for 30 s, in 57°C for 60
s and in 72°C for 60 s (40 cycles).
Detection of mutation in YMDD region. Mutation in YMDD
region were detected by sequencing and RLFP used as a screen-
ing method. Before of sequencing reaction, the part of gene of
virus's polymerase with rt204 became duplicated in single PCR
or nested-PCR reaction in dependence of HBV-DNA concentra-
tion in studied samples. Amplification were performed in mix-
ture contain 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM each dNTP, 0.5 mM each primer, 1 U DNA
polymerase and 5 ml of solution of DNA. Amplification were
performed with primer 840 (5'-ACC CCA TCT TTT TGT TTT
GTT AGG-3') and 377 primer (5'-GGA TGT GTC TGC GGC
GTT T-3'). In nested-PCR reaction external primer 12F (5'-AGA
CTC GTG GTG GAC TTC TCT-3') and 5RC (5'-CAA AAG
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AAA ATT GGT AAC AGC GGT A-3'), as well as internal
primers 840 and 377 were used (thermocycler GeneAmp PCR
System 2400 Applied Biosystems, USA) PCR were performed
according to following thermal profile: 5 min in 94°C, 40 cycles
for 30 s in 94°C, 30 s in 55°C and 60 s in 72°C and 5 min in
72°C. Cleaning of PCR products were prepared with reagents
Clean-Up (A&A Biotechnology, Poland).
Reaction of sequence were executed, using Big Dye Appren-
tice Termistor Cycle Sequencing Ready Reaction Kit (Applied
Biosystems, USA). Sequenced products were cleaned by Ex Ter-
minator Kit (A&A Biotechnology, Poland).
The sequencing was performed ABI PRISM 377 (Applied
Biosystems, USA).
HBV-DNA quantification. In order to HBV-DNA sequences in
patient's sera, PCR method with conserved region primers was
performed. Thermal cycling was achieved using the following
conditions: initial incubation at 96°C for 120 s, and then 40
cycles in 94°C for 30 s, 50°C for 30 s and 72°C for 60 s.
HBV-DNA concentration were detected in sera by real-time
PCR based on TaqMan chemistry. Amplification was performed
in 25 μl reaction mixture containing 2 × TaqMan Universal
Master Mix (Applied Biosystems) with uracil N'-glycosylase, 30
pmol of forward primer, 30 pmol of reverse primer, 30 pmol
TaqMan probe (5'-FAM) and 5 μl of isolated DNA. After incu-
bation for 2 minutes at 50°C, which enables uracil N'-glycosy-
lase to inactivate possible contaminating amplicons, incubation
for 10 min at 95°C allowed AmpliTaq Gold polymerase to acti-
vate and inactivate the uracil N'-glycosylase. The PCR cycling
program consisted of 45 two-step cycles of 15 w at 95°C and 60
s at 60°C.
Analysis of raw data was done with the Sequence Detector
V1.6.3 software (PE Biosystems). Data were collected at the
annealing step (60°C) of every cycle, and the threshold cycle
(Ct) for each sample was calculated by determining the point at
which the fluorescence exceeded the threshold limit, which was
set at 0.04 U. The standard curve was calculated automatically
by plotting the Ct values against each standard of known con-
centration. For preparation of the external standards an interna-
tional reference VQC plasma preparation panel (CLB) contain-
ing well-characterized HBV-DNA levels was used. Sample copy
numbers were calculated by interpolation of the experimentally
determined standard curve. The detection limit of this system
was as few as 10 HBV-DNA copies/ml of serum. A linear stan-
dard curve was obtained between 10 and 108 DNA template
copies/reaction.
Results
Dynamic range of HBV DNA during 2 years
of lamivudine therapy and six months after
lamivudine discontinuation based on PCR
and real time PCR
Before lamivudine treatment all children had high
(108-109 copies/ml) serum HBV DNA level. Children's
samples were divided into two groups based on the
presence of HBV DNA level after two years of lamivu-
dine treatment.
Group I included 18 (66.7%) children's sera with
HBV DNA between 104 -109 copies/ml after 2 years of
lamivudine treatment, whereas group II- 9 (33.35%)
included children's sera with HBV DNA below103
copy/ml.
After half year of lamivudine therapy all examined
patients had lower HBV DNA level when compared to
level of HBV DNA before treatment (p=0.00001).
Four (14.8%) patients (group II) had HBV DNA below
103 copies/ml. Average HBV DNA concentration for
all patients at that time was as high as 1.0 × 107
copies/ml. 
Next 6 months of lamivudine therapy showed that
HBV DNA level increased in 13 (48.2%) patients (12
from group I, 1 – group II) when compared to HBV
DNA level after half year of treatment (p=0.13).
In other 12 (44.4%) children's samples (6 – from
group I and 6 – group II) we observed that HBV DNA
decreased, however in 2 (7.4%) samples (group II)
DNA level did not change. The average concentration
of HBV DNA at that time of treatment was 1.53 × 108
copies/ml. Therefore, next half year of treatment
showed that in 13 (48.2%) children from group I
HBV DNA increased when compared to HBV DNA
level before 6 months (p=0.02), but 10 (37.03% ) of
27 patients (4 – group I, 6 – group II) had lower HBV
DNA level. In 4 (14.8%) children's sample HBV
DNA level did not change. Average concentration of
HBV DNA at that time was as high as 1.10 × 109
copies/ml. Two years of lamivudine therapy did not
cause statistical significant changes (p=0,87) in HBV
DNA concentration when compared to value after
one and half year of lamivudine treatment. Average
concentration of HBV DNA at that time was 5.75 ×
108 copies/ml
Therefore, after lamivudyne discontinuation in 21
(77,8%) children observed increased level of HBV
DNA compared to DNA level after two years after
lamivudine therapy (p=0.002).
Only 4 (14.8%) children manifested lower HBV
DNA in blood sera, but still were considered as HBV
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Fig. 1. Average concentration of HBV DNA during and after
lamivudine treatment (logarytmic graph) in total number of
patients: 1 – before treatment; 2 – half a year after treatment; 3 –
one year after treatment; 4 – year and a half after treatment; 5 –
two years after treatment; 6 – six months after lamivudine discon-
tinuation.
DNA positive. Thus, 2 (7.4%) patients were character-
ized as HBV DNA negative. Average concentration of
HBV DNA at that time of experiment was 1.16 × 1010
copies/ml.
Logarithmic graph of average concentration of
HBV DNA during and after lamivudine treatment have
been presented on Fig. 1.
Evolution of hepatitis B virus polymerase gene
mutations during 2 years of lamivudine
therapy and six months after lamivudine
discontinuation 
According to sequence analysis, a lamivudine-resistant
mutation developed in 7 (25.9%) of 27 patients after 1
year of treatment. In all 7 (25.9%) patients, the muta-
tion occurred in the YMDD motif at reverse transcrip-
tase position 204 (rt204; M204V/I). 4 (14.8%) patients
had substitution ATG→GTG whereas 3 (11.1%) other
children had substitution ATG→ATT. In two different
patients, the YMDD mutation was combined with wild
type of virus. Therefore, during treatment process wild
type of HBV was replaced by dominant mutation in
those patients. Our results didn't show any remarkable
differences (p=0.059) between number of patients with
mutation in group I and II after one year of lamivudine
therapy.
Therefore, after 1.5 year of lamivudine treatment
we observed mutation at reverse transcriptase position
204 (rt204; M204V/I) in 14 (51.8%) patients from
group I. A significant difference (p=0.0002) was
observed between number of mutation in group I and
II. Nine (33.3%) children had substitution
ATG→GTG, and the other 5 (18.5%) – ATG→ATT.
Two years of lamivudine treatment induced muta-
tion in conservative motif at reverse transcriptase in 17
(62.9%) children from group I.
A significant difference (p=0.000002) were
observed in number of mutation between two groups.
Thus, six months after lamivudine discontinuation in
23 (85.2%) YMDD mutation were replaced by wild
type of HBV virus. Only 4 (14.8%) patients displayed
mutation at positions rt204. The total number of
patients with mutation rt M204 V and rt M204 I have
been presented in Table 1.
Serological response
Before lamivudyne treatment all of the 27 children had
HBeAg and none of them had anti-HBe. After half
year of treatment in 1 (3.7%) patient from group I we
observed seroconversion. After one year of lamivudine
therapy in 3 (11.1%) patients from group II and 2 (7.4%)
from group I anti-HBe were developed, therefore sero-
conversion observed just in one patient. After one and
half year of lamivudine therapy HBeAg disappeared in 3
(11.1%) patients (1 child from group I and 2 children
from group II). Two years after treatment in 8 (29.6%)
children observed anti-HBe (6 children from group II
and two from group I) – seroconversion noticed in 6
(22.2%) cases (5 children from group II).
Therefore, half year after lamivudine discontinuation
seroconversion was observed in 4 (14.8%) children from
group II. Reseroconversion on the other hand,
appeared in 1 patient from group II after lamivudine
discontinuation. HBV DNA concentration in this
patient at that time was as high as 9 × 109 copies/ml,
whereas 2 years after lamivudine therapy was <103
copies/ml and at that time we observed seroconversion
in HBeAg/anti-HBe (Table 2).
Biochemical response
ALT activity in total number of 27 patients did not show
any significant differences during lamivudine treatment,
and after lamivudine discontinuation. Changes in ALT in
total 27 number of patients during 2 years and after
lamivudine therapy have been presented on Fig. 2. Aver-
age activity of ALT±SD in total number of patients and
in particular groups has been shown in Table 3.
Discussion
Chronic hepatitis B in children is mostly asympto-
matic, but they are at life long risk for severe compli-
cations like cirrhosis and HCC. Treatment is consid-
ered to suppress the virus and to prolong the survival
by preventing the complications. Beneficial treatment
options for children are interferon-alpha (IFN-alpha)
with antiviral, antiproliferative and immuno-modula-
tory effects and lamivudine (LAM) which inhibits
replication of HBV and increases cellular immune
response [7].
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Table 1. The total number of patients with mutation rt M204 V and rt M204 I.
Lamivudine is well tolerated and significantly
reduces HBV DNA level [8]. In our study all 27 chil-
dren had high level of HBV DNA before lamivudine
treatment. After half year of lamivudine therapy all
patients had significantly lower HBV DNA level when
compared to level of HBV DNA before treatment
(p=0.00001). Although, next months of treatment
showed that HBV DNA level increased in some
patients. Six months after lamivudine discontinuation
HBV DNA level in 21 (77.8%) children was over than
105 copies/ml. In 2 (7.4%) cases we observed virolog-
ical response. Average concentration of HBV DNA at
that time of experiment was 1.16 × 1010 copy/ml.
These children cases also showed, that long term
lamivudine therapy could induce emergence of
lamivudine resistant mutations in chronic hepatitis B
patients, but discontinuation of treatment could induce
reemergence of wild type of HBV with prior lamivu-
dine resistance. 
However, lamivudine resistance associated with
mutations in the polymerase gene, particularly in
rtM204I/V known as YMDD mutant, occurs at a rate
of 14%-30% annually [9,10]. Although, genetic mech-
anism of lamivudine resistance is known, the distant
results of lamivudine treatment in children still remain
unclear. In our study lamivudine-resistant mutation
developed in 7 (25.9%) of 27 patients after 1 year of
treatment. In addition, lamivudine-resistant mutations
were suppressed after treatment discontinuation.
Therefore, YMDD mutations were found in 4 (14.8%)
of the 27 patients after lamivudine discontinuation and
in 23 (85.2%) children mutations were replaced by
wild type of HBV. 
Sokal et al. [5] consider that treatment should be
continued, for up to 36 months, until VR, with or with-
out seroconversion, is achieved. In view of the poor
long-term response, they recommend that treatment is
discontinued if YMDD mutations emerge. It is likely
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Table 2. Serological results. *HBe+ – patients with presence of HBe in blood serum, HBe- – patients with absence of HBe in blood serum,
Anti-HBe+ – patients with anti HBe in blood serum
Table 3. Average activity of ALT±SD ( SD – standard deviation) in total number of patients and in particular groups.
that most patients will tolerate the discontinuation of
therapy in view of their mild underlying disease, and
that they will probably return to their pretreatment dis-
ease status. Sokal et al. concluded also that despite the
fact that children response to lamivudine treatment,
more than 60% of them did not meet the study end-
point. Their observation suggests the need for selec-
tion of candidates that will benefit from treatment, and
secondly the need for new therapeutic strategies, such
as combination antiviral therapy, that will provide
more potent viral suppression, and present a higher
barrier to the emergence of resistance. 
Jonas MM et al. [11] found that treatment of chron-
ic hepatitis B with lamivudine for one year is safe in
children and is superior to placebo, although neither
approach is highly efficacious. Efficacy may be
improved by selecting patients whose alanine amino-
transferase value is at least twice the upper limit of the
normal range. Jonas MM et al. suggest also, that viro-
logic and biochemical responses achieved with
lamivudine therapy are as durable as spontaneous
responses, at least for the first six months. Although,
there are data to suggest that further therapeutic
responses are achieved with longer therapy, the devel-
opment of genotypic resistance may limit the benefits
of extended therapy, since the long-term outcome of
chronic hepatitis B in children with lamivudine-resist-
ant mutants remain unknown.
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Fig. 2. Changes in ALT in total 27 number of patients during 2
years and after lamivudine therapy: 1 – before treatment; 2 – half
a year after treatment; 3 – year after treatment; 4 – year and a half
after treatment; 5 – two years after treatment; 6 – six months after
lamivudine discontinuation.
